All press coverage

Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market

Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulc...

Interview with Stefano Golinelli by Margherita Lopes – Adnkronos Salute’s PharmaKronos